Tissue Repair (ASX:TRP) Debt-to-Equity: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Tissue Repair Debt-to-Equity?

Tissue Repair ASX:TRP +8.43% Debt-to-Equity is 0.00 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 967 Biotechnology companies, Tissue Repair ranks worse than 103412.51% on this metric.

Tissue Repair's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil. Tissue Repair's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil. Tissue Repair's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$11.84 Mil. Tissue Repair's debt to equity for the quarter that ended in Dec. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Tissue Repair's Debt-to-Equity or its related term are showing as below:

ASX:TRP's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Tissue Repair  (ASX:TRP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Tissue Repair Debt-to-Equity Related Terms

Tissue Repair Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Tissue Repair's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Repair Debt-to-Equity Chart

Tissue Repair Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Equity
0.00 0.00 0.00 0.00 0.00

Tissue Repair Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:TRP vs VRTX, REGN, RVMD: Debt-to-Equity Comparison

For the Biotechnology subindustry, Tissue Repair's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Repair Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Repair's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Tissue Repair's Debt-to-Equity falls into.


Tissue Repair Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Tissue Repair's Debt to Equity Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 13.912
=0.00

Tissue Repair's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 11.835
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Tissue Repair (ASX:TRP) has a Debt-to-Equity of 0.00 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tissue Repair and its competitors. According to the industry distribution chart, Tissue Repair ranks #999999 out of 967 companies in the Biotechnology industry.
Is Tissue Repair's Debt-to-Equity too high?
Tissue Repair's current Debt-to-Equity is 0.00. Based on the distribution chart, Tissue Repair ranks #999999 out of 967 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Tissue Repair's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tissue Repair ranks #999999 out of 967 companies for Debt-to-Equity. This places Tissue Repair in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tissue Repair and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Repair's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Repair stock overvalued right now?
Tissue Repair (ASX:TRP) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Tissue Repair (ASX:TRP), the current Debt-to-Equity is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tissue Repair Business Description

Address 821 Pacific Highway, Tower A, Level 9, The Zenith, Chatswood, NSW, AUS, 2067
Tissue Repair Ltd is a clinical-stage biopharmaceutical company engaged in development of wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies.